CMTR-CHEMTRAK FDA OK Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CMTR-CHEMTRAK FDA OK

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Art Baer who wrote (247)	1/21/1997 11:01:00 PM
From: surfinSteve	of 1172

Fourth quarter ended Year Ended December 31 December 31 1996 1995 l996 l995 Net revenues: Product sales $443 $236 $2,463 $2,171 Funded research and other 423 3600 598 4,725 Total revenues 866 3,836 3,061 6,896 Product sales seem to be up both on a yearly and quarterly basis. There is income from $423K in funded research...isn't that the Hp Check milestone payment? According to the text accompanying the earnings figures: Product revenues for 1996 are primarily from ChemTrak's cholesterol test, while funded research revenues include milestone payments from Astra Merck associated with the license agreement for U.S. rights to the rapid H. Pylori test, HpChek. You wrote: The products sales do not include Hp Check except milestone payments from Astra Merck (I think). ... On the negative side Cholestrek sales fell quarter over quater. Are we looking at the same earnings report? Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next